Toshiba Receives FDA Clearance for Two CT Clinical Applications

TUSTIN, California — March 28, 2008 — Toshiba America Medical Systems, Inc. has received FDA clearance for two new CT clinical applications that will improve throughput and enhance workflow, while further reducing contrast and radiation dosage. The applications, SURECardio™ Prospective and Variable Helical Pitch (vHP), are available for new Toshiba AquilionTM 32- and 64-slice CT systems.

SURECardio Prospective
Toshiba's SURECardio Prospective helps reduce patient dose by up to 80 percent during coronary CTA exams by using a helical acquisition technique to provide one continuous image instead of multiple images produced by the current step-and-shoot techniques. SURECardio Prospective will automatically detect and adjust to patients with arrthymia, providing quicker, more conclusive exam results.

Variable Helical Pitch
Variable Helical Pitch (vHP) increases workflow and efficiency by enabling physicians to complete an exam of more than one anatomical region consecutively — i.e. without stopping to alter the helical pitch of the exam. Toshiba is the first vendor to introduce this type of technique.

source: Toshiba Medical